CL2019001353A1 - Compuestos con actividad antitumoral contra células cancerígenas que portan mutaciones en el exón 20 de egfr o her2. - Google Patents

Compuestos con actividad antitumoral contra células cancerígenas que portan mutaciones en el exón 20 de egfr o her2.

Info

Publication number
CL2019001353A1
CL2019001353A1 CL2019001353A CL2019001353A CL2019001353A1 CL 2019001353 A1 CL2019001353 A1 CL 2019001353A1 CL 2019001353 A CL2019001353 A CL 2019001353A CL 2019001353 A CL2019001353 A CL 2019001353A CL 2019001353 A1 CL2019001353 A1 CL 2019001353A1
Authority
CL
Chile
Prior art keywords
her2
egfr
exon
compounds
cancer cells
Prior art date
Application number
CL2019001353A
Other languages
English (en)
Inventor
Jacqulyne Robichaux
Monique Nilsson
John V Heymach
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of CL2019001353A1 publication Critical patent/CL2019001353A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Abstract

LA PRESENTE INVENCIÓN PROPORCIONA MÉTODOS PARA TRATAR CÁNCER EN UN PACIENTE DETERMINADO POR TENER UNA MUTACIÓN EN EL EXÓN 20 DE EGFR Y/O HER2, COMO UNA MUTACIÓN DE INSERCIÓN, MEDIANTE LA ADMINISTRACIÓN DE UN INHIBIDOR DE TIROSINA QUINASA DE TERCERA GENERACIÓN, COMO POZIOTINIB O AFATINIB.
CL2019001353A 2016-11-17 2019-05-17 Compuestos con actividad antitumoral contra células cancerígenas que portan mutaciones en el exón 20 de egfr o her2. CL2019001353A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662423732P 2016-11-17 2016-11-17
US201662427692P 2016-11-29 2016-11-29
US201762572716P 2017-10-16 2017-10-16

Publications (1)

Publication Number Publication Date
CL2019001353A1 true CL2019001353A1 (es) 2019-11-08

Family

ID=62146809

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019001353A CL2019001353A1 (es) 2016-11-17 2019-05-17 Compuestos con actividad antitumoral contra células cancerígenas que portan mutaciones en el exón 20 de egfr o her2.

Country Status (18)

Country Link
US (2) US11446302B2 (es)
EP (1) EP3541832A4 (es)
JP (2) JP7265985B2 (es)
KR (2) KR102585006B1 (es)
CN (2) CN110291104B (es)
AU (2) AU2017363199B2 (es)
BR (1) BR112019010020A2 (es)
CA (1) CA3044432A1 (es)
CL (1) CL2019001353A1 (es)
CO (1) CO2019006218A2 (es)
CU (1) CU20190051A7 (es)
EC (1) ECSP19043254A (es)
MA (1) MA46852A (es)
MX (1) MX2019005834A (es)
PE (1) PE20191303A1 (es)
PH (1) PH12019501116A1 (es)
TW (1) TWI782931B (es)
WO (1) WO2018094225A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018330171A1 (en) * 2017-09-08 2020-03-12 The Regents Of The University Of Colorado, A Body Corporate Compounds, compositions and methods for treating or preventing HER-driven drug-resistant cancers
TW202005651A (zh) * 2018-06-25 2020-02-01 美商光譜製藥公司 波齊替尼(poziotinib)與抗her1、her2或her4抗體之組合及使用彼之方法
TW202019412A (zh) * 2018-06-25 2020-06-01 美商光譜製藥公司 波齊替尼(poziotinib)與細胞毒性劑及／或其他分子靶向劑之組合及其用途
TW202012391A (zh) * 2018-07-04 2020-04-01 日商第一三共股份有限公司 二芳基醚型喹唑啉衍生物
SG11202101712XA (en) * 2018-09-14 2021-04-29 Spectrum Pharmaceuticals Inc Kits and methods for treating cancers
CN113056272A (zh) * 2018-09-21 2021-06-29 光谱医药公司 新的喹唑啉egfr抑制剂
WO2020132633A1 (en) * 2018-12-21 2020-06-25 Board Of Regents, The University Of Texas System Combination therapy for the treatment of cancer
CN113840842A (zh) 2019-02-26 2021-12-24 詹森生物科技公司 利用双特异性抗EGFR/c-Met抗体的联合疗法和患者分层
WO2020205632A1 (en) * 2019-03-29 2020-10-08 Board Of Regents, The University Oftexas System Compounds with anti-tumor activity against cancer cells bearing her2 exon 21 insertions
KR20210149103A (ko) * 2019-03-29 2021-12-08 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 Egfr 또는 her2 엑손 20 삽입을 지니는 암 세포에 대한 항종양 활성을 갖는 화합물
US20220175779A1 (en) * 2019-04-17 2022-06-09 Board Of Regents, The University Of Texas System Compounds against cancer bearing tyrosine kinase inhibitor resistant egfr mutations
EP3955928A4 (en) * 2019-04-17 2023-05-31 Board of Regents, The University of Texas System COMPOUNDS HAVING ANTITUMORIC ACTIVITY AGAINST CANCER CELLS WITH TYROSINE KINAS INHIBITOR-RESISTANT EGFR MUTATIONS
US11850248B2 (en) 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
JOP20210304A1 (ar) 2019-05-14 2023-01-30 Janssen Biotech Inc علاجات مركبة باستخدام الأجسام المضادة ثنائية النوعية المضادة لمستقبل عامل نمو البشرة (EGFR)/ مستقبل عامل نمو خلايا الكبد (c-Met) ومثبطات كيناز التيروسين الخاصة بمستقبل عامل نمو البشرة (EGFR) من الجيل الثالث
CA3148413A1 (en) * 2019-08-23 2021-03-04 Guru Reddy Poziotinib combination with vegfr2 inhibitors and methods of use thereof
KR20220133238A (ko) * 2020-01-29 2022-10-04 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 Nrg1 융합체가 있는 암의 치료를 위한 포지오티닙의 용도
CN111658650B (zh) * 2020-05-28 2022-05-06 南通大学 Mln4924在制备脉络膜新生血管治疗药物中的应用
TW202211923A (zh) * 2020-07-27 2022-04-01 美商光譜製藥公司 波奇替尼(poziotinib)於非小細胞肺癌之治療
JP2023543528A (ja) 2020-09-23 2023-10-16 スコーピオン セラピューティクス インコーポレイテッド がんの処置に有用なピロロ［３，２－ｃ］ピリジン－４－オン誘導体
WO2022072645A2 (en) 2020-09-30 2022-04-07 Scorpion Therapeutics, Inc. Methods for treating cancer
WO2022072632A1 (en) 2020-09-30 2022-04-07 Scorpion Therapeutics, Inc. Bicyclic compounds for use in the treatment cancer
TW202229282A (zh) 2020-09-30 2022-08-01 美商史考皮恩治療有限公司 治療癌症之方法
WO2022094271A1 (en) 2020-10-30 2022-05-05 Scorpion Therapeutics, Inc. Methods for treating cancer
WO2022098992A1 (en) 2020-11-05 2022-05-12 Scorpion Therapeutics, Inc. Use of macrocyclic compounds in methods of treating cancer
CA3210156A1 (en) * 2021-01-29 2022-08-04 Board Of Regents, The University Of Texas System Methods of treating cancer with poziotinib
WO2022189942A1 (en) 2021-03-09 2022-09-15 Janssen Biotech, Inc. Treatment of cancers lacking egfr-activating mutations
WO2022197913A1 (en) 2021-03-18 2022-09-22 Scorpion Therapeutics, Inc. Bicyclic derivatives which can be used to treat cancer
WO2023015149A1 (en) * 2021-08-02 2023-02-09 Spectrum Pharmaceuticals, Inc. Treatment of non-small cell lung cancer with poziotinib
TW202342057A (zh) 2022-02-07 2023-11-01 美商健生生物科技公司 用於減少用ｅｇｆｒ／ｍｅｔ雙特異性抗體治療之患者的輸注相關反應之方法
WO2023173083A1 (en) 2022-03-11 2023-09-14 Scorpion Therapeutics, Inc. Tetrahydroindole derivatives as egfr and/or her2 inhibtors useful for the treatment of cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19911509A1 (de) 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE10042058A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
BRPI0414489A8 (pt) 2003-09-16 2019-01-15 Astrazeneca Ab derivado de quinazolina, composição farmacêutica, uso de um derivado de quinazolina, e, processo para a preparação de um derivado de quinazolina
DE10349113A1 (de) 2003-10-17 2005-05-12 Boehringer Ingelheim Pharma Verfahren zur Herstellung von Aminocrotonylverbindungen
BRPI0607358A2 (pt) 2005-02-04 2009-09-01 Boeringer Ingelheim Internat Gmbh uso de inibidores de tirosina quinase para o tratamento da rinossinusite crÈnica, bem como medicamento
CN101516376A (zh) * 2006-09-18 2009-08-26 贝林格尔.英格海姆国际有限公司 用于治疗携带egfr突变的癌症的方法
SI2068880T1 (sl) * 2006-09-18 2012-08-31 Boehringer Ingelheim Int Postopek za zdravljenje raka, ki vsebuje mutacije EGFR
US8137919B2 (en) * 2008-04-10 2012-03-20 Montefiore Medical Center Method of determining the sensitivity of cancer cells to EGFR inhibitors including cetuximab, panitumumab and erlotinib
PE20100252A1 (es) 2008-06-06 2010-04-12 Boehringer Ingelheim Int Nuevas formulaciones farmaceuticas solidas que comprenden dimaleato de 4-[(3-cloro-4-fluorofenil) amino]-6-{[4-(n,n-dimetilamino)-1-oxo-2-buten-1-il] amino}-7-((s)-tetrahidrofuran-3-iloxi)-quinazolina
KR101317809B1 (ko) 2011-06-07 2013-10-16 한미약품 주식회사 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물
AU2013355260B2 (en) 2012-12-04 2019-07-25 Caris Mpi, Inc. Molecular profiling for cancer
KR101906688B1 (ko) * 2013-08-22 2018-10-10 다이호야쿠힌고교 가부시키가이샤 신규 퀴놀린 치환 화합물

Also Published As

Publication number Publication date
JP2020502059A (ja) 2020-01-23
CO2019006218A2 (es) 2020-01-17
EP3541832A4 (en) 2020-09-30
EP3541832A1 (en) 2019-09-25
BR112019010020A2 (pt) 2019-08-20
AU2023266384A1 (en) 2023-12-07
CN110291104B (zh) 2023-11-03
AU2017363199A1 (en) 2019-07-04
PH12019501116A1 (en) 2019-11-25
AU2017363199B2 (en) 2023-08-17
MX2019005834A (es) 2019-10-14
US11446302B2 (en) 2022-09-20
KR102585006B1 (ko) 2023-10-05
JP7265985B2 (ja) 2023-04-27
TW201825098A (zh) 2018-07-16
US20230233563A1 (en) 2023-07-27
MA46852A (fr) 2019-09-25
CN117599061A (zh) 2024-02-27
KR20190085980A (ko) 2019-07-19
ECSP19043254A (es) 2019-09-30
PE20191303A1 (es) 2019-09-23
WO2018094225A1 (en) 2018-05-24
CA3044432A1 (en) 2018-05-24
JP2023100682A (ja) 2023-07-19
US20200316071A1 (en) 2020-10-08
CU20190051A7 (es) 2020-01-03
TWI782931B (zh) 2022-11-11
KR20230145496A (ko) 2023-10-17
CN110291104A (zh) 2019-09-27

Similar Documents

Publication Publication Date Title
CL2019001353A1 (es) Compuestos con actividad antitumoral contra células cancerígenas que portan mutaciones en el exón 20 de egfr o her2.
DOP2019000163A (es) Compuestos de 7-feniletilamino-4h-pirimido[4,5-d][1,3]-oxazin-2-ona como inhibidores de idh1 e idh2 mutantes
MX2021004881A (es) Combinacion de palbociclib y rad1901 para usarse en el tratamiento de cancer de mama en un sujeto con cancer positivo a receptor de estrogeno.
MX2021013218A (es) Composiciones y metodos para el tratamiento del cancer usando una terapia con celulas t modificadas con tet2.
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
NI201400095A (es) Metodos para el tratamiento del cáncer de pulmon de celulas no pequeñas utilizando terapia combinada de inhibidor tor cinasa.
GT201700246A (es) Métodos y kits para tratar la depresión
PH12015502161A1 (en) Therapeutic compounds and compositions
BR112016029041A2 (pt) terapia de combinação com inibidores de glutaminase
MX2020009773A (es) Terapia de combinacion.
MX2020001727A (es) Terapia de combinacion.
BR112021019489A2 (pt) Compostos com atividade antitumoral contra células cancerosas portando inserções do éxon 20 de egfr ou de her2
MX2015014599A (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tracar cancer.
MX2017005134A (es) Tratamiento del cáncer con inmunoestimuladores.
MX2019013862A (es) Terapia de combinacion.
MX2023000549A (es) Combinaciones para el tratamiento de neoplasias usando localizacion de celulas quiescentes e inhibidores de egfr.
BR112017021700A2 (pt) composições terapêuticas e métodos de uso para o tratamento do câncer
TR201811308T4 (tr) Kanser kok hücrelerini azaltan anti-emp2 tedavisi.
PH12020551495A1 (en) Compounds with anti-tumor activity against cancer cells bearing her2 exon 19 mutations
EP3991749A3 (en) A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody
BR112021019376A2 (pt) Compostos com atividade antitumor contra células cancerígenas transportando inserções de éxon 21 de her2
WO2019043176A3 (en) HISTONE-DEACETYLASE INHIBITOR IN COMBINATION WITH ANTIMETABOLITE AGENT FOR CANCER THERAPY
BR112019002458A2 (pt) composições e métodos para tratar câncer com depleção de arginina e agentes imuno-oncológicos
MX2021007554A (es) Terapia de combinacion para el tratamiento de cancer.
CL2023003090A1 (es) Combinaciones de composiciones terapéuticas y usos para tratar cánceres